Pharmadrug Inc Stock Price, News & Analysis

Welcome to our dedicated page for Pharmadrug news (Ticker: LMLLF), a resource for investors and traders seeking the latest updates and insights on Pharmadrug stock.

PharmaDrug Inc. (OTC Pink: LMLLF) generates news primarily around specialty pharmaceutical development, corporate strategy and financing activities. Company releases describe a focus on the research, development and commercialization of controlled-substances and natural medicines, including psychedelics and previously approved drugs, with particular emphasis on cepharanthine and its reformulated version PD-001 through majority-owned Sairiyo Therapeutics.

News updates frequently cover progress in the cepharanthine program, such as stability studies for PD-001 and regulatory milestones supporting first-in-human Phase 1 clinical studies in Australia for viral infectious diseases. These items provide context on how PharmaDrug is advancing its clinical pipeline and working with contract development and manufacturing organizations to prepare trial material.

Another recurring theme in PharmaDrug’s news flow is strategic and corporate development. The company has reported a strategic review process led by a special committee to evaluate its assets, research programs and capital structure. It has also announced decisions regarding its subsidiary SecureDose Synthetics Inc., including the decision to cease activities there and concentrate on therapeutic molecules and medical products.

Investors following LMLLF can also expect updates on PharmaDrug’s collaboration with Canurta Limited Partnership and Canurta Inc., including letters of intent, definitive agreements and tranche closings for PharmaDrug’s planned equity interest in Canurta. Financing-related news, such as the issuance or restructuring of secured convertible debentures and associated warrants, is another key category of announcements.

By reviewing this news feed, readers can monitor developments in PharmaDrug’s clinical programs, its work in natural and psychedelic medicines, its botanical therapeutics collaboration with Canurta and its ongoing capital structure and strategic review activities.